Shares of biotechnology company Unity Biotechnology (NASDAQ:UBX) are flying high today on promising data from a Phase 2 study evaluating UBX1325 for the treatment of diabetic macular edema (DME).
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Impressively, at 24 weeks post a single dose, subjects saw a +7.6 ETDRS letter improvement from baseline. Further, the injection also showed a favorable safety and tolerability profile.
The company now plans to begin a pivotal study for DME in H2 2023.
Read full Disclosure
